NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Tag: Duchenne’s muscular dystrophy

6/25/2018

‘Home run’ gene therapy for Duchenne muscular dystrophy: Investor-oriented coverage pitches promise but …

6/9/2017

5-Star Friday: Emotions vs. evidence

3 9/28/2016

What some stories missed about the muscular dystrophy drug approval: Pharma’s close ties to vocal patient advocacy groups

3 6/22/2016

What’s at stake in the FDA’s decision on eteplirsen, an experimental muscular dystrophy drug